Xi'an Kintai Biotech Inc is one of the most experienced manufacturers and suppliers of Equol Powder in China. Please feel free to wholesale high quality Equol Powder for sale here from our factory. For price consultation, contact us.
KINTAIBIO® relies on high-quality fresh raw materials and specializes in the production of premium-grade equol. We also offer customized services to meet the diverse needs of different customers. We have established a full-process quality control system covering everything from raw material screening to finished product release, ensuring that each batch meets industry standards for purity, solubility, and stability. If you are looking for a stable and reliable supply of equol, please contact us at pharm@kintaibio.com.
Contact Us Now To Get Samples!
Equol is an active metabolite produced in the gut by specific bacteria from soy isoflavones; it does not exist directly in soybeans. Approximately 30%–50% of the population harbor gut bacteria capable of converting daidzein into equol. These 'equol producers' obtain higher levels of bioactive substances after consuming soy products. Because its bioactivity is significantly higher than that of its precursor soy isoflavones, equol has attracted sustained attention in areas such as women's health, chronic disease risk intervention, and livestock and poultry farming.
Equol is a non-steroidal isoflavan compound that exists in two optical isomers, (S)-equol and (R)-equol. The form naturally present in the human body and possessing high bioactivity is (S)-equol. Structurally, it resembles the endogenous estrogen 17β-estradiol, but its affinity for estrogen receptor β (ERβ) is far higher than for ERα-its affinity for ERβ is approximately 13 times that for ERα. This receptor selectivity is an important molecular basis distinguishing it from classic hormone replacement therapy: it tends to activate ERβ pathways associated with anti-inflammatory effects, neuroprotection, and vasodilation, while having a relatively weak effect on ERα-dominated proliferation signals in the breast and endometrium.
The production of equol is highly dependent on individual gut microbiota composition. Daidzein in soy products is converted into S-equol through a series of transformations including deglycosylation and reduction by gut bacteria. This capacity shows a clear 'producer/non-producer' binary distribution in the population.
How to make Equol?
equol benefits
Research on the benefits of equol has concentrated on several directions: menopausal symptom management, cardiovascular and metabolic protection, bone health, and vascular and cognitive aging.
a. Menopausal Symptoms and Quality of Life
This is the area with the relatively largest accumulation of randomized controlled trials. A double-blind, randomized, placebo-controlled trial enrolled perimenopausal or menopausal women aged 40–65 who received 10 mg S-equol or placebo daily for 12 weeks. In the intention-to-treat analysis, the reduction in vasomotor symptoms (VMS) did not reach statistical significance between groups; the authors attributed this to the large placebo effect commonly seen in VMS studies. However, in the high-symptom subgroup with more than 9 daily VMS episodes at baseline, the S-equol group showed significant advantages: vaginal irritation, itching, and soreness were all significantly reduced; the emotional health domain improved; and the anger-hostility, total mood disturbance, and vigor-activity dimensions of the POMS scale also showed change patterns different from the placebo group. In addition, the S-equol group showed significant increases in sleep minutes and time in bed from baseline to 12 weeks, whereas the placebo group showed no such change. The trial concluded that for perimenopausal and menopausal women with frequent VMS episodes, S-equol brings improvements in multiple quality-of-life indicators including sleep, mood, and vaginal health.
Another randomized, double-blind, active-controlled trial compared S-equol with soy isoflavones for hot flashes. 102 postmenopausal women with ≥5 daily hot flashes were assigned to 10, 20, or 40 mg/day S-equol groups or a soy isoflavone group for 8 weeks. At week 8, the reduction in hot flash frequency was similar across groups, but in the 8-week cumulative effect analysis, 40 mg/day S-equol was superior to isoflavones. Subgroup analysis showed that for women with more than 8 daily hot flashes at baseline, both 20 mg and 40 mg S-equol were superior to isoflavones. In addition, 10 mg and 20 mg S-equol were superior to isoflavones in improving muscle and joint pain scores. This study suggests that the benefits of S-equol are more pronounced in populations with a high symptom burden, and that it has independent value for somatic symptoms beyond hot flashes.
B. Bone Health
Evidence on bone health is relatively specific, but sample sizes are limited. A 1-year randomized, double-blind, placebo-controlled trial tested 2 mg, 6 mg, and 10 mg/day S-equol in 93 Japanese postmenopausal women confirmed to be equol non-producers. The 10 mg dose group showed a nearly 24% decrease in urinary deoxypyridinoline from baseline, compared with only about 3% in the placebo group, and whole-body bone mineral density was maintained during the intervention. Another 12-month trial combined 10 mg/day S-equol with 25 mg/day resveratrol in 60 postmenopausal women and found significant improvements in bone turnover markers, with a statistically significant increase in whole-body bone mineral density compared with placebo. These data support the potential of S-equol to inhibit bone resorption and maintain bone density in non-producer postmenopausal women, but the studies are small and require larger independent verification.
C. Cancer Risk
The relationship between equol and cancer presents a complex picture in observational studies. The EPIC cohort (Netherlands) included 383 breast cancer cases and 383 controls and found no association between plasma equol and breast cancer risk. However, in ER-positive cases, urinary equol was associated with increased risk. A cross-sectional study based on NHANES reported an inverted U-shaped association between urinary equol and cancer risk: below 25.5 ng/ml, higher equol levels were associated with increased risk; above this threshold, risk instead decreased. The authors also noted that the study was cross-sectional, could not infer causality, and that over 88% of participants had urinary equol levels in the lower range. These findings are insufficient to support any definitive conclusion about equol being cancer-preventive or carcinogenic; more conclusions await further clinical trial verification.
d. Cardiovascular and Metabolic Health
In the direction of vascular aging and cognition, a large ongoing trial deserves attention. The ACE trial is the first large randomized controlled trial evaluating the effects of equol on vascular and cognitive aging. It uses a multicenter, double-blind, placebo-controlled design at the University of Pittsburgh, Wake Forest University, and Emory University, enrolling 369 community-dwelling adults aged 65–85 without dementia, randomized to 10 mg/day equol or placebo for 24 months. The primary outcome is arterial stiffness assessed by carotid-femoral pulse wave velocity; secondary outcomes include white matter lesion volume and a preclinical Alzheimer's cognitive composite score. The trial's design paper notes that equol has shown vascular protective and antioxidant effects in preclinical studies and has emerging neuroprotective properties, but its role in preventing vascular aging and cognitive decline in humans had not previously been explored. Outcome data from this trial have not yet been reported, so it can currently only be positioned as 'high-quality evidence in accumulation' rather than a confirmed benefit.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11229234/
https://www.sciencedirect.com/science/article/pii/S0022316622131962
https://www.sciencedirect.com/science/article/abs/pii/S0955286316300195
Uses of Equol
Dietary Supplements and Functional Foods
Dietary supplements and functional foods are the application direction closest to consumers. In Japan and the United States, equol-containing tablets and capsules have been launched as dietary supplements or entered clinical trials. The ACE trial used 10 mg/day for 24 months; the menopausal symptom trial likewise used 10 mg/day for 12 weeks; and in the bone health trial, 10 mg/day was shown to be effective for bone resorption markers. 10 mg/day can be regarded as the most consistent dose reference in current research. At the functional food level, equol can be added as a functional ingredient, targeting middle-aged and older women with menopausal health management needs, but product positioning should be based on 'improving quality of life in high-symptom populations' rather than generalized 'chronic disease prevention'.
Livestock and Poultry Farming
Livestock and poultry farming is a direction in which equol research has relatively solid data accumulation but commercialization is not yet mature. Soy isoflavones are widely present in feed, and studies on direct equol supplementation in livestock and poultry show effects in improving meat quality and alleviating oxidative stress. Because equol's bioactivity is higher than that of its precursors, adding it to feed may be more controllable than relying on endogenous conversion in the animal gut. The significance of this direction lies in providing a non-antibiotic functional additive approach for healthy animal farming, but it remains primarily at the research trial stage.
Cosmetics and Topical Preparations
Cosmetics and topical preparations are a recently emerging extension. Equol's antioxidant and anti-inflammatory properties make it suitable for anti-aging and soothing skincare products. Public information indicates that S-equol is typically used as a cosmetic ingredient at 0.1%–3%. Systemic exposure from topical use is far lower than from oral administration, so safety concerns are relatively smaller, but human efficacy evaluation data remain to be substantiated.
Safety and Side Effects of Equol
Safety of Equol: Based on existing animal experiments, equol at levels far exceeding daily human supplementation levels has not shown obvious organ toxicity; blood parameters, organ weights, and tissue examinations have revealed no problems, genotoxicity tests have basically passed, and no obvious adverse irritation to the uterus has been observed in rats and monkeys. Overall, the safety record is good.
Side effects of Equol: The main signals come from some in vitro experiments and long-term high-dose animal experiments: some cell studies suggest that equol at higher concentrations may have slight effects on genetic material, and long-term high-dose feeding to mice has been associated with decreased brain antioxidant capacity and increased apoptosis. These findings are quite far from the situation of people taking low-dose supplements in daily life, and their clinical significance is unclear, but they indicate that whether long-term high-dose consumption is completely harmless still lacks sufficient human data.
equol producer
KINTAIBIO® is a professional plant extract manufacturer supplying high-quality equol to customers worldwide. Whether for small sample quantities or long-term bulk procurement, we can provide flexible supply solutions tailored to customer needs.
We offer traceable raw materials, customized supply solutions, and a full set of COA, MSDS, test reports, and batch quality documents. Our team will provide competitive pricing based on different order volumes and delivery requirements. If you are looking for a stable and reliable source of equol, please contact us at pharm@kintaibio.com.
FAQ
Q: Does equol cause weight gain?
A: Current research evidence does not support the claim that 'equol causes weight gain'; rather, it tends to be associated with lower body weight or body fat levels. In rat experiments, the group receiving equol actually showed a lower magnitude of weight gain than the control group. In human observational studies, postmenopausal women capable of producing equol had significantly lower rates of overweight and visceral obesity than women unable to produce equol. Another study of Chinese adults also found that people with higher urinary equol concentrations had more favorable liver fat content and body fat indicators. However, these are mainly correlational studies and cannot directly prove causality, but at least they suggest that equol is unlikely to be a factor causing weight gain.
Q: What is equol good for?
A: The most studied benefits of equol center on metabolic and immune regulation. Metabolically, people capable of producing equol tend to have lower body fat and lower obesity risk, which is related to gut microbiota and changes in certain metabolites. Cardiovascularly, animal experiments show that equol can dilate blood vessels and lower blood pressure in hypertensive rats, suggesting potential benefits for blood pressure regulation. Immunologically, some studies have found that equol can inhibit excessive activation of basophils in allergic reactions, showing anti-allergic potential. In addition, some research suggests that equol may reduce lung inflammatory damage caused by influenza virus through immune response regulation. It should be noted that most of these benefits come from laboratory or observational studies, and human clinical evidence remains limited.
Hot Tags: Equol Powder, China Equol Powder manufacturers, suppliers, factory, Bulk Powder Omega 3, Schisandra Berry Extract Powder, Tribulus Terrestris Extract Powder
